Eli Lilly and Company $LLY Shares Purchased by Hazlett Burt & Watson Inc.

Key Points

• Hazlett Burt & Watson Inc. increased its holdings in Eli Lilly and Company by 20.7% in Q2, now owning 1,840 shares valued at approximately $1.43 million.
• Eli Lilly's stock is currently priced at $833.08, down 2.6%, with a market capitalization of $788.47 billion and a P/E ratio of 54.45.
• Despite recent stock price fluctuations, Eli Lilly beat quarterly earnings expectations with $6.31 EPS and $15.56 billion in revenue, reflecting a 37.6% increase year-over-year.

Hazlett Burt & Watson Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,840 shares of the company's stock after acquiring an additional 316 shares during the period. Hazlett Burt & Watson Inc.'s holdings in Eli Lilly and Company were worth $1,434,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Hobbs Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC increased its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares during the last quarter. Ascent Capital Management LLC boosted its position in shares of Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners boosted its position in shares of Eli Lilly and Company by 2.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.6%

LLY opened at $833.08 on Monday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a 50 day simple moving average of $742.42 and a 200-day simple moving average of $765.55. The stock has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on LLY shares. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the company an "overweight" rating in a research report on Thursday. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. Finally, Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $948.06.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jamere Jackson acquired 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.14% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.